Trine Strandgaard

The paper identifies atypical B cells (ABCs) as mediators of poor response to BCG immunotherapy in high-risk NMIBC patients, linking their expansion and FCRL5 expression to early recurrence.

This study shows that low T cell receptor diversity in bladder cancer patients is linked to poor outcomes and identifies TCR diversity as a potential biomarker for treatment.

This study identifies the HLA-E/NKG2A axis as a therapeutic target in BCG-unresponsive bladder cancer by showing its role in immune evasion and impaired effector cell function.